Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state.


Bayazit A., Kilinc Y.

Pediatrics international : official journal of the Japan Pediatric Society, cilt.43, sa.6, ss.592-6, 2001 (SCI-Expanded) identifier identifier identifier

Özet

Background: Patients with sickle cell anemia (SCA) run the risk of having decreased levels of natural coagulation inhibitors. This may he due to either hemostatic abnormalities or hepatic dysfunction. This study is designed to evaluate coagulation profiles of patients with SCA in it steady state and to determine whether hypercoagulable state is present or not.